Literature DB >> 6251496

dl-9a-Deoxy-9a-methylene-PGI2 (a stable prostacyclin derivative): preliminary pharmacological data.

R Ceserani, M Grossoni, D Longiave, B Mizzotti, O Pozzi, A Dembinska-Kiec, S Bianco.   

Abstract

Carboprostacyclin (dl-9a-deoxy-9a-methylene-PGI2), a new stable PGI2-analogue, has been studied in vitro and in vivo. This analogue relaxes bovine coronary artery (potency ratio to PGI2 = 0.17), inhibits human PRP aggregation induced by ADP (IC50 = 12.5 nM2), deaggregates platelet clumps in cat heparinized blood (ED50 = 10.4 microgram/kg) and raises cAMP content in human PRP, but is less potent than PGI2. It is less potent (about 30 times) than PGI2 in lowering blood pressure in anaesthetized rats, inhibits basal gastric secretion in the rat and is 8 and 6 times less potent than PGE2 in protecting rat gastric mucosa from the lesions induced by stress and ASA, respectively, and about half as potent as PGE2 in protecting intestinal mucosa from damage by indomethacin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6251496     DOI: 10.1016/0161-4630(80)90100-7

Source DB:  PubMed          Journal:  Prostaglandins Med        ISSN: 0161-4630


  2 in total

1.  The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro.

Authors:  K Schrör; H Darius; R Matzky; R Ohlendorf
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-06       Impact factor: 3.000

2.  (5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets.

Authors:  A Corsini; G C Folco; R Fumagalli; S Nicosia; M A Noe; D Oliva
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.